Pilot study with clozapine in patients with HIV‐associated psychosis and drug‐induced parkinsonism
Identifieur interne : 003441 ( Istex/Checkpoint ); précédent : 003440; suivant : 003442Pilot study with clozapine in patients with HIV‐associated psychosis and drug‐induced parkinsonism
Auteurs : Gabriel Lera [Argentine] ; Jorge Zirulnik [Argentine]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-01.
Descripteurs français
- Wicri :
- topic : Sida.
English descriptors
- KwdEn :
Abstract
Clozapine (CZP) is an atypical antipsychotic drug that does not appear to block striatal dopamine receptors. In six patients who met the criteria of HIV‐associated psychosis and who had previously developed moderate parkinsonism as a result of the use of typical neuroleptic agents, CZP was added in an open, rising dose study. Subjects were evaluated at baseline after at least 7 days without neuroleptic drugs and then monthly for 3 months of the experimental treatment using three rating scales: Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). A significant reduction in psychopathology as represented in the BPRS total score (54.2 at baseline versus 23.9 at month 3) and CGI (2 and 8, respectively) was obtained with a mean CZP dose of 27.08 mg/day. Parkinsonism also improved by an average of 76.5% at the end of the study. One patient did not complete the study as a result of a progressive decrease in leukocyte count while on CZP. These preliminary results suggest that the pharmacologic properties of CZP may be of value in the management of HIV‐psychotic patients.
Url:
DOI: 10.1002/1531-8257(199901)14:1<128::AID-MDS1021>3.0.CO;2-J
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:F3514D890CE81D4FA4105F21E36338F918E14D17Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pilot study with clozapine in patients with HIV‐associated psychosis and drug‐induced parkinsonism</title><author><name sortKey="Lera, Gabriel" sort="Lera, Gabriel" uniqKey="Lera G" first="Gabriel" last="Lera">Gabriel Lera</name></author><author><name sortKey="Zirulnik, Jorge" sort="Zirulnik, Jorge" uniqKey="Zirulnik J" first="Jorge" last="Zirulnik">Jorge Zirulnik</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F3514D890CE81D4FA4105F21E36338F918E14D17</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199901)14:1<128::AID-MDS1021>3.0.CO;2-J</idno><idno type="url">https://api.istex.fr/document/F3514D890CE81D4FA4105F21E36338F918E14D17/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002B67</idno><idno type="wicri:Area/Istex/Curation">002B67</idno><idno type="wicri:Area/Istex/Checkpoint">003441</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pilot study with clozapine in patients with HIV‐associated psychosis and drug‐induced parkinsonism</title><author><name sortKey="Lera, Gabriel" sort="Lera, Gabriel" uniqKey="Lera G" first="Gabriel" last="Lera">Gabriel Lera</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Neurology and Infectology Units, Juan A. Fernández Hospital, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Zirulnik, Jorge" sort="Zirulnik, Jorge" uniqKey="Zirulnik J" first="Jorge" last="Zirulnik">Jorge Zirulnik</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Neurology and Infectology Units, Juan A. Fernández Hospital, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-01">1999-01</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="128">128</biblScope><biblScope unit="page" to="131">131</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F3514D890CE81D4FA4105F21E36338F918E14D17</idno><idno type="DOI">10.1002/1531-8257(199901)14:1<128::AID-MDS1021>3.0.CO;2-J</idno><idno type="ArticleID">MDS1021</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Antipsychotic agents</term><term>Clozapine</term><term>Extrapyramidal symptoms</term><term>HIV‐associated psychosis</term><term>Secondary parkinsonism</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Sida</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clozapine (CZP) is an atypical antipsychotic drug that does not appear to block striatal dopamine receptors. In six patients who met the criteria of HIV‐associated psychosis and who had previously developed moderate parkinsonism as a result of the use of typical neuroleptic agents, CZP was added in an open, rising dose study. Subjects were evaluated at baseline after at least 7 days without neuroleptic drugs and then monthly for 3 months of the experimental treatment using three rating scales: Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). A significant reduction in psychopathology as represented in the BPRS total score (54.2 at baseline versus 23.9 at month 3) and CGI (2 and 8, respectively) was obtained with a mean CZP dose of 27.08 mg/day. Parkinsonism also improved by an average of 76.5% at the end of the study. One patient did not complete the study as a result of a progressive decrease in leukocyte count while on CZP. These preliminary results suggest that the pharmacologic properties of CZP may be of value in the management of HIV‐psychotic patients.</div></front></TEI><affiliations><list><country><li>Argentine</li></country></list><tree><country name="Argentine"><noRegion><name sortKey="Lera, Gabriel" sort="Lera, Gabriel" uniqKey="Lera G" first="Gabriel" last="Lera">Gabriel Lera</name></noRegion><name sortKey="Zirulnik, Jorge" sort="Zirulnik, Jorge" uniqKey="Zirulnik J" first="Jorge" last="Zirulnik">Jorge Zirulnik</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003441 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 003441 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:F3514D890CE81D4FA4105F21E36338F918E14D17
|texte= Pilot study with clozapine in patients with HIV‐associated psychosis and drug‐induced parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |